Literature DB >> 23594675

Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor.

Sina M Coldewey1, Areeg I Khan, Amar Kapoor, Massimo Collino, Mara Rogazzo, Michael Brines, Anthony Cerami, Peter Hall, Michael Sheaff, Julius E Kieswich, Muhammed M Yaqoob, Nimesh S A Patel, Christoph Thiemermann.   

Abstract

The β-common receptor (βcR) plays a pivotal role in the nonhematopoietic tissue-protective effects of erythropoietin (EPO). Here we determined whether EPO reduces the acute kidney injury (AKI) caused by sepsis and whether this effect is mediated by the βcR. In young (2 months old) C57BL/6 wild-type and βcR knockout mice, lipopolysaccharide caused a significant increase in serum urea and creatinine, hence AKI. This AKI was not associated with any overt morphological alterations in the kidney and was attenuated by EPO given 1 h after lipopolysaccharide in wild-type but not in βcR knockout mice. In the kidneys of endotoxemic wild-type mice, EPO enhanced the phosphorylation of Akt, glycogen synthase kinase-3β, and endothelial nitric oxide synthase, and inhibited the activation of nuclear factor-κB. All these effects of EPO were lost in βcR knockout mice. Since sepsis is more severe in older animals or patients, we tested whether EPO was renoprotective in 8-month-old wild-type and βcR knockout mice that underwent cecal ligation and puncture. These older mice developed AKI at 24 h, which was attenuated by EPO treatment 1 h post cecal ligation and puncture in wild-type mice but not in βcR knockout mice. Thus, activation of the βcR by EPO is essential for the observed reduction in AKI in either endotoxemic young mice or older mice with polymicrobial sepsis, and for the activation of well-known signaling pathways by EPO.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23594675     DOI: 10.1038/ki.2013.118

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  41 in total

1.  Effects of erythropoietin receptor activity on angiogenesis, tubular injury, and fibrosis in acute kidney injury: a "U-shaped" relationship.

Authors:  Mingjun Shi; Brianna Flores; Peng Li; Nancy Gillings; Kathryn L McMillan; Jianfeng Ye; Lily Jun-Shen Huang; Sachdev S Sidhu; Yong-Ping Zhong; Maria T Grompe; Philip R Streeter; Orson W Moe; Ming Chang Hu
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-29

2.  Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models.

Authors:  Florian E Tögel; Jon D Ahlstrom; Ying Yang; Zhuma Hu; Ping Zhang; Christof Westenfelder
Journal:  J Am Soc Nephrol       Date:  2016-03-16       Impact factor: 10.121

3.  IκB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD.

Authors:  Jianmin Chen; Julius E Kieswich; Fausto Chiazza; Amie J Moyes; Thomas Gobbetti; Gareth S D Purvis; Daniela C F Salvatori; Nimesh S A Patel; Mauro Perretti; Adrian J Hobbs; Massimo Collino; Muhammad M Yaqoob; Christoph Thiemermann
Journal:  J Am Soc Nephrol       Date:  2016-05-06       Impact factor: 10.121

4.  Erythropoietin reduces acute lung injury and multiple organ failure/dysfunction associated to a scald-burn inflammatory injury in the rat.

Authors:  Joao Rocha; Maria Eduardo-Figueira; Andreia Barateiro; Adelaide Fernandes; Dora Brites; Rui Pinto; Marisa Freitas; Eduarda Fernandes; Helder Mota-Filipe; Bruno Sepodes
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

5.  Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis.

Authors:  Thomas Gobbetti; Sina M Coldewey; Jianmin Chen; Simon McArthur; Pauline le Faouder; Nicolas Cenac; Roderick J Flower; Christoph Thiemermann; Mauro Perretti
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

6.  Renoprotective effect of erythropoietin in zebrafish after administration of gentamicin: an immunohistochemical study for β-catenin and c-kit expression.

Authors:  Valeria Cernaro; Alessandra Sfacteria; Claudia Rifici; Francesco Macrì; Giulia Maricchiolo; Antonio Lacquaniti; Carlo Alberto Ricciardi; Antoine Buemi; Giuseppe Costantino; Domenico Santoro; Michele Buemi
Journal:  J Nephrol       Date:  2016-09-27       Impact factor: 3.902

7.  A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice.

Authors:  M Collino; E Benetti; M Rogazzo; F Chiazza; R Mastrocola; D Nigro; J C Cutrin; M Aragno; R Fantozzi; M A Minetto; C Thiemermann
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 8.  Bridging Translation by Improving Preclinical Study Design in AKI.

Authors:  Mark de Caestecker; Ben D Humphreys; Kathleen D Liu; William H Fissell; Jorge Cerda; Thomas D Nolin; David Askenazi; Girish Mour; Frank E Harrell; Nick Pullen; Mark D Okusa; Sarah Faubel
Journal:  J Am Soc Nephrol       Date:  2015-11-04       Impact factor: 10.121

9.  Computational design and experimental characterization of a novel β-common receptor inhibitory peptide.

Authors:  Cody R Kilar; Sivakumar Sekharan; Larysa Sautina; YanPeng Diao; Shahar Keinan; Yong Shen; Jorg Bungert; Rajesh Mohandas; Mark S Segal
Journal:  Peptides       Date:  2018-04-07       Impact factor: 3.750

10.  The Impact of Erythropoietin on Short- and Long-Term Kidney-Related Outcomes in Neonates of Extremely Low Gestational Age. Results of a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial.

Authors:  David J Askenazi; Patrick J Heagerty; Robert H Schmicker; Patrick Brophy; Sandra E Juul; Stuart L Goldstein; Sangeeta Hingorani
Journal:  J Pediatr       Date:  2021-01-20       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.